Swiss drug major Roche (RHHBY) reported that its group sales for the first-quarter declined 6% to 14.40 billion Swiss francs from 15.32 billion francs last year. At constant exchange rates, quarterly sales increased 2% as strong demand for newer medicines as well as diagnostics products including immunodiagnostics, clinical chemistry tests and advanced staining solutions more than offset the anticipated decline in COVID-19-related sales and the impact of biosimilar/generic erosion.
After the latest quarter, the impact of the drop in COVID-19-related sales is largely over and there will be no further material impact on Group sales.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.